NCT04204057 2024-08-13
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Rhizen Pharmaceuticals SA
Phase 2 Completed
Clinical Trials
6 trialsNCT05021900 2024-08-13
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Rhizen Pharmaceuticals SA
Phase 2 Completed
NCT03711604 2024-05-08
Compassionate Use Study of Tenalisib (RP6530)
Rhizen Pharmaceuticals SA
Phase 1/2 Completed
NCT03770000 2022-10-28
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Rhizen Pharmaceuticals SA
Phase 1/2 Completed
NCT03711578 2021-08-12
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Rhizen Pharmaceuticals SA
Phase 2 Completed
NCT02567656 2020-01-13
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Rhizen Pharmaceuticals SA
Phase 1 Completed